NCT04799990

Study to Assess Adverse Events When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Real World Setting

Post-Marketing Real World Safety Study of Risankizumab in the United States

• Status: Withdrawn
• Phase: —
• Study type: Observational
• Enrollment: 0 (actual)
• Sponsor: AbbVie · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Study is not recruiting and using secondary data sources only

Detailed description

Study is not recruiting and using secondary data sources only

Conditions

• Psoriasis

Interventions

Type	Name	Description
DRUG	Risankizumab	Subcutaneous Injection
BIOLOGICAL	Comparator 1	Subcutaneous or Intravenous Injection
DRUG	Comparator 2	Oral, Opthalmic, Subcutaneous or Intravenous Injection

Timeline

• Start date: 2021-06-23
• Primary completion: 2022-03-10
• Completion: 2022-03-10
• First posted: 2021-03-16
• Last updated: 2022-12-09

Regulatory

• FDA-regulated drug study